Scientific Overview
Bell's palsy is an acute, unilateral, peripheral (lower motor neuron) facial nerve paralysis of idiopathic (unknown) cause, though a reactivation of latent herpes simplex virus type 1 (HSV-1) or varicella-zoster virus (VZV) is the most widely accepted pathophysiological hypothesis. It is the most common cause of acute facial nerve palsy, with an annual incidence of approximately 11–40 per 100,000 population.
Importantly, up to 30% of patients with Bell's palsy may fail to achieve complete facial recovery. This is a clinically significant fact that should inform patient counselling; the original document's statement that 'most patients experience significant recovery' — while broadly accurate — should not create false reassurance.
PRIMARY: Gronseth GS, Paduga R. Evidence-based guideline update: steroids and antivirals for Bell palsy. AAN Guideline Development Subcommittee. Neurology. 2012;79(22):2209–2213. doi:10.1212/WNL.0b013e318275978c [Reaffirmed by AAN: February 25, 2023]
SUPPORTING: Rim HS, et al. Optimal Bell's Palsy Treatment: Steroids, Antivirals, and a Timely and Personalized Approach. J Clin Med. 2023;13(1):51. doi:10.3390/jcm13010051
SUPPORTING: Dalrymple SN, Row JH, Gazewood J. Bell Palsy: Rapid Evidence Review. AFP. 2023 Apr 15;107(4):399–404.
Evidence-Based Treatment — Critical Correction
The following treatment recommendations reflect current AAN guideline evidence levels:
1. Corticosteroids (prednisolone/prednisone): AAN Level A recommendation. Should be offered to all patients with new-onset Bell's palsy to increase probability of recovery of facial nerve function. Most effective when initiated within 72 hours of symptom onset. Recommended regimen: prednisolone 50 mg/day for 10 days or prednisone 60 mg/day for 5 days with 5-day taper.
2. Antiviral agents (acyclovir, valacyclovir): AAN Level C recommendation — only in COMBINATION with steroids (not as monotherapy). May be offered as combination therapy. Benefit not firmly established; if present, it is likely modest (<7% additional improvement over steroids alone). Patients should be counselled accordingly.
3. Eye protection: Essential to prevent exposure keratopathy and corneal injury when lagophthalmos (inability to fully close the eye) is present. Artificial tears, lubricating eye ointment at night, moisture chambers, and taping the eyelid closed at night are all appropriate measures.
Bell's Palsy — Associated Symptoms Covered
The following symptoms (Pages 27–34) are all recognized manifestations of Bell's palsy involving the facial nerve (cranial nerve VII) and its branches:
- Inability to close the eye (lagophthalmos) — due to orbicularis oculi weakness
- Drooping of the corner of the mouth — due to orbicularis oris and depressor anguli oris weakness
- Altered taste (dysgeusia) — involvement of chorda tympani branch carrying taste from anterior 2/3 of tongue
- Drooling — due to orbicularis oris weakness impairing lip seal
- Ear pain (otalgia) — may precede or accompany facial palsy; relates to geniculate ganglion involvement
- Hyperacusis — due to stapedius muscle weakness (stapedius branch of facial nerve)
- Dry eye — reduced lacrimation from greater petrosal nerve involvement; paradoxically tear drainage may be impaired causing overflow epiphora
- Excessive tearing (epiphora) — impaired tear drainage due to eyelid laxity
|
🔴 RED FLAGS — Seek Emergency Care Immediately
• Facial weakness with limb weakness — suggests stroke, not Bell's palsy
• Facial weakness with parotid mass — suggests parotid malignancy
• Bilateral facial palsy — consider Lyme disease, Guillain-Barré, sarcoidosis
• Forehead sparing — suggests upper motor neuron (central) lesion; STROKE until proven otherwise
• Vesicles in ear canal with facial palsy — consider Ramsay Hunt syndrome (VZV reactivation); requires antiviral treatment
|
